Beyond their role as a cellular powerhouse, mitochondria are emerging as integral players
in molecular signaling and cell fate determination through reactive oxygen species (ROS) …

Many treatments have been identified that confer robust cardioprotection in experimental
animal models of acute ischemia and reperfusion injury. However, translation of these …

Ischemia/reperfusion injury (IRI) permeates a variety of diseases and is a ubiquitous
concern in every transplantation proceeding, from whole organs to modest grafts. Given its …

The potential for ischemic preconditioning to reduce infarct size was first recognized more
than 30 years ago [180]. Despite extension of the concept to ischemic postcondition‑ing …

Reperfusion is mandatory to salvage ischemic myocardium from infarction, but reperfusion
per se contributes to injury and ultimate infarct size. Therefore, cardioprotection beyond that …

Acute myocardial infarction (MI) is a major cause of death and disability worldwide. In
patients with MI, the treatment of choice for reducing acute myocardial ischemic injury and …

Ischaemic heart disease and the heart failure that often results, remain the leading causes of
death and disability in Europe and worldwide. As such, in order to prevent heart failure and …

Cardiovascular disease is the leading cause of death in western countries. Among
cardiovascular diseases, myocardial infarction represents a life-threatening condition …

The mitochondrial permeability transition pore (MPTP) is a non-specific pore that opens in
the inner mitochondrial membrane (IMM) when matrix [Ca 2+] is high, especially when …

The coronary circulation is both culprit and victim of acute myocardial infarction. The rupture
of an epicardial atherosclerotic plaque with superimposed thrombosis causes coronary …